Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive reported human factors and PK validation results for Anaphylm™ (dibutepinephrine) supporting an FDA NDA resubmission in Q3 2026. Packaging/IFU revisions cut median pouch opening time from 17s to 3s and reduced incorrect film placement by over 80% (e.g., difficulty opening: 26/166 to 1/105; incorrect administration: 20/166 to 2/105), with no observed chewing/removal and no observed administration errors in the self-administration PK arm. Top-of-tongue misplacement still produced clinically meaningful PD/PD response (Cmax >100 pg/mL; median Tmax 35 min), and the company reiterated plans to complete resubmission less than 8 months after receiving the January 2026 FDA Complete Response Letter.

Analysis

This materially de-risks the “human factors” failure mode, which was the cheapest reason for the stock to exist at a deep discount. The key market mechanism is not the topline PK itself but the fact that FDA’s prior objections look increasingly procedural rather than a fundamental efficacy problem, which should compress the probability-weighted downside on AQST over the next 1-3 months. That said, the remaining decision is binary and regulatory: the agency may still ask for more data, and small-cap biotech tends to reprice violently if the resubmission is accepted but the review clock is extended.

The bigger second-order effect is competitive validation for the non-invasive epinephrine category. If AQST ultimately clears, it expands investor confidence that alternative delivery formats can win share from legacy autoinjectors, which is more important for SPRY than for the injectors themselves; however, AQST’s differentiated packaging and oral-film format may still leave it with a narrower real-world adoption ceiling than bulls assume. In other words, approval would likely be enough for a rerating, but not enough to assume broad physician conversion or rapid payer pull-through.

The contrarian point is that the market may be underestimating how much of the value here is already in the base case after the CRL shock: if the next FDA interaction is clean, upside is real, but the stock can still stall once the headline fades because commercialization risk shifts from regulatory to distribution, reimbursement, and training. Falsifier for the bullish setup is any FDA request for another usability or administration study, or a resubmission acceptance delay into 2027. For that reason, this is better treated as a catalyst trade than a long-duration fundamental compounder until the agency response is visible.

Key Decisions for Investors

• AQST: tactical long into the planned Q3 resubmission window, with the position sized as a binary-event trade rather than a core holding; take partial profits on a clean FDA accept/review notice, and cut if the agency asks for another study.
• AQST calls: use limited-risk upside exposure only if implied volatility remains below the post-CRL peak; structure as 3-6 month call spreads to capture a rerating without paying for unlimited regulatory tail risk.
• Pair trade: long AQST / short SPRY on the thesis that positive validation of a second non-invasive epinephrine platform expands category credibility but does not yet justify full multiple parity for the incumbent; revisit if SPRY usage metrics accelerate faster than expected.
• Watch item: if AQST trades above the pre-CRL gap level before FDA acceptance, fade strength into the event and reduce exposure, because the next leg likely depends on regulatory confirmation rather than additional efficacy color.